

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A transdermal therapeutic system for continuous administration of pramipexol comprising

a backing layer and a first active ingredient-containing polymer layer disposed on the backing layer which comprises the active ingredient pramipexol, wherein the first active ingredient-containing polymer layer comprises at least one pressure-sensitive adhesive polymer selected from carboxyl group-free polyacrylates, where the active ingredient pramipexol is present in said first active ingredient-containing polymer layer in a proportion of between 40 and 40 25 to less than 75 % by weight

and said transdermal therapeutic system includes ~~an additional~~ a second active ingredient-containing polymer layer disposed on the first active ingredient-containing polymer layer, said second active ingredient-containing polymer layer comprising at least one pressure-sensitive adhesive polymer selected from carboxyl group-free polyacrylates, where the active ingredient pramipexol is present in said second active ingredient-containing polymer layer in a proportion of between 2 and 10 % by weight, whereby the transdermal therapeutic system releases the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ hr}$ over the period between 24 hours after administration to 72 hours after administration.

2. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, which further comprises at least one element selected from the group consisting of a pressure-sensitive adhesive layer, a membrane which controls the rate of release of pramipexol, an active ingredient-containing layer or a supporting layer.

3. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the pressure-sensitive adhesive polymer is a carboxyl group-free polyacrylate which can be prepared by polymerization of a monomer mixture of at least one acrylic ester or methacrylic ester with linear, branched or cyclic aliphatic C₁-C₁₂ substituents without other functional groups, and at least one hydroxyl group-containing acrylic ester or one hydroxyl group-containing methacrylic ester in a proportion by weight of less than 10%.

4. (Canceled)

5. (Canceled)

6. (Previously Presented) The transdermal therapeutic system as claimed in claim 3, wherein the monomer mixture additionally comprises vinyl acetate in a proportion by weight of less than 50 %.

7. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present in the active ingredient-containing polymer layer in dissolved, emulsified and/or dispersed form.

8. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer, *R*-(+) enantiomer or racemic mixture of these two enantiomers in the active ingredient-containing polymer layer.

9. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present as a free base, hydrate, solvate and/or pharmaceutically acceptable salt in the active ingredient-containing polymer layer.

10. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer in the form of a free base in the active ingredient-containing polymer layer.

11. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein said transdermal therapeutic system delivers the active ingredient pramipexol continuously to a patient's skin over a period of from 4 to 7 days.

12. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, which is able to release the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ h}$ over the period between 24 hours after administration to 168 h after administration.

13. (Canceled)

14. (Currently Amended) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present in said first active ingredient-containing polymer layer in a proportion of between ~~40~~ 25 and ~~25~~ 40 % by weight.

15. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the daily delivery rate of pramipexol is between 0.1-10 mg.

16. (Currently Amended) The transdermal therapeutic system as claimed in claim 3, wherein the pressure-sensitive adhesive monomer mixture additionally comprises vinyl acetate in a proportion of less than 25% by weight and the pressure-sensitive adhesive does not comprise water or an aqueous dispersion.

17. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the daily delivery rate of pramipexol is between 0.5 to 4.5 mg.

18. (Currently Amended) A transdermal therapeutic system for continuous administration of pramipexol comprising (i) a backing layer, (ii) a first active ingredient-containing polymer layer comprising pramipexol in a proportion of between 10 and less than 75

% by weight and (iii) a second active ingredient-containing polymer layer comprising pramipexol in a proportion of between 2 and 10 % by weight,

wherein the first and second active ingredient-containing polymer layer comprise pressure-sensitive adhesive polymer consisting of carboxyl group-free polyacrylates,

and said transdermal therapeutic system releases the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ hr}$ over the period between 24 hours after administration to 72 hours after administration in the absence of an excipient or penetration-promoter and said system has no additional pressure sensitive top plaster.